Smart-HRT: smartwatch-based monitoring and real-time tracking for optimizing hormone replacement therapy efficacy in menopause

Active Grant Awarded

Award ID
R43AG099614
Recipient
Awarding agency
Obligated
$313,211

Award facts

Assistance listing
93.866 Aging Research
Completion date 18% complete
Place of performance
North Carolina, USA

Award details come from USAspending.gov.

About this award

The National Institute on Aging, within the Department of Health and Human Services' National Institutes of Health, awarded Amissa Inc. $313,211 on September 17, 2026, under Assistance Listing 93.866, Aging Research. The award is Grant R43AG099614, a Phase I SBIR feasibility project titled SMART-HRT: Smartwatch-Based Monitoring and Real-Time Tracking for Optimizing Hormone Replacement Therapy Efficacy in Menopause.

The project will develop machine learning models to remotely diagnose and monitor hot flashes and night sweats in menopausal women wearing widely available, consumer smartwatches, using real-life physiological and behavioral data collected from those devices. The stated goal is to improve understanding of vasomotor symptoms without costly medical devices or in-person laboratory sleep studies.

Dollars obligated are $313,211, equal to the award amount. The period of performance runs from September 17, 2026, through September 16, 2027. Place of performance is North Carolina, USA.

The NIA program funds biomedical, social, and behavioral research directed toward understanding the aging process and the diseases and needs of aging people, with a particular emphasis on preventing and treating Alzheimer's disease and related dementias.

Description

Abstract
50 million women in the U.S. Are in menopause and approximately 80% of individuals will experience painful vasomotor symptoms, including hot flashes and night sweats, that last seven years on average. Women, generally between the ages of 45-65, experience decreased hormone levels, triggering diverse symptoms that result in poor sleep, pain, and fatigue (among many other symptoms) which negatively impact their work and quality of life. To manage symptoms, menopausal women are commonly, and often inappropriately, prescribed antidepressants and sleep medications which have negative side effects including nervousness, restlessness, insomnia, and weight gain. Prior research suggests that the persistent poor-quality sleep women experience during menopause increases a woman's risk of cognitive decline and alzheimer's disease. One potential explanation for why two-thirds of the 6.2 million americans with alzheimer's disease are women could be elucidated by this emerging evidence. Unfortunately, current techniques to objectively measure menopauserelated vasomotor symptoms require costly and burdensome medical devices and/or in-person sleep studies in a laboratory environment. Even worse, roughly 50% of U.S. Counties lack a single OB/GYN and more than 9.5 million women live in areas without access to care. Based on this team's prior use of smartwatches for menopause and alzheimer's research, we aim to improve the understanding of vasomotor symptoms in menopausal women by using smartwatches to collect real-life physiological and behavior data. Specifically, this phase I sbir feasibility research will develop machine learning models to remotely diagnose and monitor hot flashes and night sweats in menopausal women wearing widely available, stigma-free, consumer smartwatches. Similar use of wearables to monitor women's menstrual cycles has received FDA 510(K) approval. Phase I efforts will demonstrate proof-of-concept and feasibility for the use of amissa health's existing smartwatch software application to provide appropriate biosignal data to develop digital biomarkers for the remote monitoring and prediction of vasomotor symptoms. We will collect real-life objective patient-generated health data and selfreported hot flash, night sweat, and sleep interruption event information from 50 perimenopausal women in realworld settings. If successful, this research will enable improved monitoring of menopausal women by trained clinicians and seed data for the discovery of low-cost and personalized lifestyle and behavior interventions that reduce the frequency, severity, duration, and persistence of painful menopause symptoms. This would reduce the unnecessary use of first-line prescription anti-depressants and sleep medications which menopause guidelines suggested have little to no evidence of helping to improve psychological symptoms. Data collected from this research and subsequent alzheimer's focused studies will pollinate longitudinal epidemiological research that identifies behavioral and lifestyle interventions to improve sleep thus potentially reducing women's risk/S of developing cognitive decline and alzheimer's disease.

Quick answers

Who received award R43AG099614?

R43AG099614 was awarded to Amissa Inc. by National Institute on Aging (National Institutes of Health) on September 17, 2026.

How much is award R43AG099614 worth?

$313,211 has been obligated on R43AG099614.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award